Home

Medication access research, pharmaceutical policy awareness, and public health education for patients..

Independent Health Education

Understand what your medication really costs
and how to pay less

For HIV, hepatitis C, weight-management, and blood-thinner prescriptions, the price you are quoted is rarely the price you have to pay. We explain what these medications actually cost and walk you through the assistance programs, copay cards, and public programs that can lower it — in plain language.

Free and low-cost pathways first Physician-reviewed We do not sell medication No ads, no referral fees

“When a prescription costs more than a paycheck, the problem is rarely a lack of options — it is that the options are buried, confusing, or never explained. We exist to surface them.”

We route patients to every free and low-cost pathway first, in plain language anyone can act on.

Four areas where cost gets in the way of care

We stay narrow on purpose. In each of these areas, treatment works — but the price keeps people from starting or staying on it. We cover what each medication costs and every way to pay less.

🧬
HIV Treatment & Management

Modern antiretroviral therapy can suppress HIV to undetectable levels within weeks — making transmission effectively impossible and life expectancy equivalent to the general population. But choosing the right regimen, understanding costs, and accessing assistance programs requires detailed, up-to-date information.

Antiretroviral therapyBiktarvyDescovyPrEPCost & access
🔬
Hepatitis C

Hepatitis C is now curable in 95%+ of patients with 8–12 weeks of direct-acting antivirals — yet millions remain undiagnosed or untreated due to cost barriers and lack of awareness. We cover genotype-specific treatment regimens, cure rates, insurance coverage, and how to access patient assistance programs.

Direct-acting antiviralsEpclusaMavyretCure ratesFibrosis staging
🩸
Anticoagulants

Blood thinners like Eliquis and Xarelto prevent strokes and dangerous clots, but the manufacturer list price runs roughly $600 a month. Most patients never need to pay that: copay cards can bring the cost to as little as $10 a month for eligible insured patients, and assistance programs help those who are uninsured. We map every route.

EliquisXareltoCouponsPatient assistanceCost & access
⚕️
Weight Management

GLP-1 receptor agonists have redefined what is medically achievable in obesity treatment. With 15–22% body weight reductions now possible and strong cardiovascular benefit data, the conversation has shifted from willpower to biology. We cover the clinical evidence, candidacy criteria, and how to discuss options with a physician.

GLP-1 agonistsSemaglutideTirzepatideBMI & candidacy

The need is not abstract

These conditions affect tens of millions of people. For many of them, the deciding factor in whether they get treated is not the medicine — it is whether they can afford it.

1.2M
People living with HIV in the US — and about 1 in 8 do not know their status (CDC)
2.4M
Americans estimated to have hepatitis C, many undiagnosed despite a curative treatment (CDC, 2017–2020)
40%
Of US adults meet the clinical criteria for obesity — a leading driver of preventable chronic disease (CDC, 2021–2023)

Cost should not decide treatment. Choosing an HIV regimen, starting hepatitis C treatment, or staying on a prescribed blood thinner are decisions that work best when cost is not the deciding factor. Accurate, physician-reviewed information — including the assistance programs that lower what patients pay — supports better choices at the point of decision.

The same standard on every page

A few things hold true across everything we publish.

Clinically accurate

All dosing, efficacy figures, and safety information are verified against current FDA prescribing information and published clinical trial data.

Physician-reviewed

Every article carries a named, credentialed medical reviewer whose specialization is relevant to the topic. No anonymous review.

Fully referenced

Clinical claims link to primary sources — trial publications, FDA labels, and clinical guidelines — not secondary media reports.

Conflict-free

No pharmaceutical advertising, no sponsored content, no affiliate commissions on medication purchases. Commercial separation is absolute.

Dated & versioned

Every page shows a visible publication date and last-reviewed date, matched to the schema markup for accurate indexing.

Clearly communicated

Clinical precision is non-negotiable — but so is clarity. Content is written to be understood by an informed adult without a medical degree.

Read our full editorial policy →

Medical Editor: Prof. Dr. Jürgen K. Rockstroh oversees medical content across SunnyPharma. View editorial team →
Scroll to Top